Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 414

1.

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.

Devlin N, Herdman M, Pavesi M, Phung, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S.

Health Qual Life Outcomes. 2017 Jun 23;15(1):130. doi: 10.1186/s12955-017-0704-y.

2.

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.

Mahajan K, Malla P, Lawrence HR, Chen Z, Kumar-Sinha C, Malik R, Shukla S, Kim J, Coppola D, Lawrence NJ, Mahajan NP.

Cancer Cell. 2017 Jun 12;31(6):790-803.e8. doi: 10.1016/j.ccell.2017.05.003.

PMID:
28609657
3.

Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.

Crona DJ, Whang YE.

Cancers (Basel). 2017 Jun 12;9(6). pii: E67. doi: 10.3390/cancers9060067. Review.

4.

An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells.

Azeem W, Hellem MR, Olsen JR, Hua Y, Marvyin K, Qu Y, Lin B, Ke X, Øyan AM, Kalland KH.

PLoS One. 2017 Jun 1;12(6):e0177861. doi: 10.1371/journal.pone.0177861. eCollection 2017.

6.

Current status and perspectives of patient-derived xenograft models in cancer research.

Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P.

J Hematol Oncol. 2017 May 12;10(1):106. doi: 10.1186/s13045-017-0470-7. Review.

7.

Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma.

Kanda T, Takahashi K, Nakamura M, Nakamoto S, Wu S, Haga Y, Sasaki R, Jiang X, Yokosuka O.

Cancers (Basel). 2017 May 5;9(5). pii: E43. doi: 10.3390/cancers9050043.

8.

Androgen Receptor as a Potential Target for Treatment of Breast Cancer.

Wu Y, Vadgama JV.

Int J Cancer Res Mol Mech. 2017 Apr;3(1). doi: 10.16966/2381-3318.129. Epub 2016 Oct 6.

9.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

10.

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.

Ho Y, Dehm SM.

Endocrinology. 2017 Jun 1;158(6):1533-1542. doi: 10.1210/en.2017-00109.

PMID:
28368512
11.

Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Groner AC, Brown M.

J Clin Invest. 2017 Apr 3;127(4):1126-1135. doi: 10.1172/JCI88885. Epub 2017 Apr 3.

12.

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM.

Cancer Cell. 2017 Apr 10;31(4):532-548.e7. doi: 10.1016/j.ccell.2017.02.017. Epub 2017 Mar 23.

PMID:
28344039
13.

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.

Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK.

Transl Oncol. 2017 Jun;10(3):357-366. doi: 10.1016/j.tranon.2017.01.011. Epub 2017 Mar 24.

14.

The steroid metabolome in the isolated ovarian follicle and its response to androgen exposure and antagonism.

Lebbe M, Taylor AE, Visser JA, Kirkman-Brown J, Woodruff TK, Arlt W.

Endocrinology. 2017 Feb 23. doi: 10.1210/en.2016-1851. [Epub ahead of print]

PMID:
28323936
15.

ELF5-Mediated AR Activation Regulates Prostate Cancer Progression.

Li K, Guo Y, Yang X, Zhang Z, Zhang C, Xu Y.

Sci Rep. 2017 Mar 13;7:42759. doi: 10.1038/srep42759.

16.

HLBT-100: a highly potent anti-cancer flavanone from Tillandsia recurvata (L.) L.

Lowe HIC, Toyang NJ, Watson CT, Ayeah KN, Bryant J.

Cancer Cell Int. 2017 Mar 7;17:38. doi: 10.1186/s12935-017-0404-z. eCollection 2017.

17.

AR Signaling in Breast Cancer.

Rahim B, O'Regan R.

Cancers (Basel). 2017 Feb 24;9(3). pii: E21. doi: 10.3390/cancers9030021. Review.

18.

Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer.

Smolle MA, Bauernhofer T, Pummer K, Calin GA, Pichler M.

Int J Mol Sci. 2017 Feb 22;18(2). pii: E473. doi: 10.3390/ijms18020473. Review.

19.

Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.

Ajiboye AS, Esopi D, Yegnasubramanian S, Denmeade SR.

Prostate. 2017 Jun;77(8):829-837. doi: 10.1002/pros.23323. Epub 2017 Feb 22.

PMID:
28224650
20.

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.

Rebello RJ, Pearson RB, Hannan RD, Furic L.

Genes (Basel). 2017 Feb 16;8(2). pii: E71. doi: 10.3390/genes8020071. Review.

Supplemental Content

Support Center